AAM taps John Murphy as president and CEO
The Association for Accessible Medicines has named John A. Murphy, III to be its next president and CEO. Murphy will join AAM in October.
Murphy most recently served as the chief policy officer at the Biotechnology Innovation Organization, where he led BIO’s legal, policy and international initiatives for the organization’s healthcare portfolio.
Keren Haruvi, president of Sandoz North America and chair of the AAM board of directors, said, “John’s decades-long experience in policy, advocacy, and communications on drugs and biologics makes him the right person to lead our industry’s efforts to advocate for policies to increase patient access to lower-cost generic and biosimilar medicines.”
[Read more: AAM: Generic medicines increase patient access more than government negotiated price controls]
Prior to BIO, Murphy served as an assistant general counsel at the Pharmaceutical Research and Manufacturers of America, where he provided legal counsel to PhRMA's policy, government affairs and alliance development teams, advising on U.S. healthcare reform, FDA engagement and healthcare payment policy. He also previously worked at the law firm Hogan Lovells, where he advised clients on federal and state healthcare fraud investigations, FDA and CMS regulations and compliance efforts related to federal and state fraud and abuse laws.
“The generic and biosimilars industry provides over 90% of prescribed medicines, is the backbone of access for many patients, and the key component to addressing health care costs in the United States,” Murphy said. “But this critical industry is at risk and is taken for granted by policymakers and the healthcare system in general. I look forward to helping amplify the voice and reach of this industry in Washington as we work hard to ensure affordable medicines remain the critical connector of healthcare and patient health in the United States.”
[Read more: AAM, Biosimilars Council releases statement on statement on Senate Judiciary Markup of PREVAIL and PERA]
Haruvi continued, “We are confident that John will lead the association’s talented team to support our work with Congress and the Administration to ensure that the generic and biosimilar industries remain sustainable and patient access to affordable medicine is prioritized. I, along with the entire board, would like to thank David Gaugh for his leadership guiding AAM during our search for a CEO.”